Former executives from the autologous chimeric antigen receptor T-cell (CAR-T) therapy developer Juno Therapeutics Inc., following the company's $9bn acquisition by Celgene Corp. last year, have launched a new company called Sana Biotechnology Inc. that's creating allogeneic engineered cells as novel therapies.
But while the endeavor is reminiscent of Allogene Therapeutics Inc. – launched last year by former Kite Pharma...